RA Capital backs a Philly biotech's $118M crossover as it aims to break into the hypertension space
While the hypertension market becomes ever more crowded with candidates as J&J tosses its hat into the ring, a Pennsylvania-based startup is looking to carve its own path with backing from some notable names attached.
Mineralys Therapeutics out of Philadelphia has completed a $118 million Series B financing with backing from RA Capital Management and Andera Partners, the biotech announced Wednesday. The company plans to use the proceeds to continue advancing its lead drug candidate, MLS-101, for patients with uncontrolled hypertension.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,400+ biopharma pros reading Endpoints daily — and it's free.